More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

Even though he suffers from psoriasis, Joel Thomas considers himself a lucky man. Psoriasis is a chronic skin disorder that affects over seven and a half million Americans. Many are not as lucky ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered biologics.

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, but there are also over-the-counter products that can help manage flare-ups ...

Plaque psoriasis, the most common form of psoriasis, is a type of autoimmune condition where the body’s immune cells attack its own healthy cells. Bimzelx was approved for the treatment of ...

A 40-year-old Hispanic man presented for treatment of dermatitis on his elbows and knees that had been evident for 5 years (Figure 1). He also had scaling plaques ... was made of psoriasis and ...

Philadelphia Eagles tight end Dallas Goedert spoke to PEOPLE following his 2025 Super Bowl win over the Kansas City Chiefs.

Injectable drugs such as methotrexate and biologics may help clear up plaques and reduce inflammation. Biologics often help when other treatments haven’t worked to treat psoriasis. They’re ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label ...

Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for all the estimated eight ...

Gumokimab is the eighth successfully approved drug developed independently by Akeso (with six already approved for market), and it is also the third non-oncology innovative drug, following ebronucimab ...